MCID: BRN035
MIFTS: 51

Brain Stem Glioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Brain Stem Glioma

MalaCards integrated aliases for Brain Stem Glioma:

Name: Brain Stem Glioma 12 15
Brainstem Neuroglial Tumor 12
Glioma of Brainstem 73
Brainstem Glioma 6

Classifications:



External Ids:

Disease Ontology 12 DOID:4202
NCIt 50 C8501
UMLS 73 C0677865

Summaries for Brain Stem Glioma

Disease Ontology : 12 A brain stem cancer that is characterized by mass lesion of the brainstem, associated cranial nerve nuclei and long tracts, has material basis in abnormally proliferating cells, derives from glial cells.

MalaCards based summary : Brain Stem Glioma, also known as brainstem neuroglial tumor, is related to diffuse intrinsic pontine glioma and glioma. An important gene associated with Brain Stem Glioma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Prednisone and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia : 76 A brainstem glioma is a cancerous glioma tumor in the brainstem. Around 75% are diagnosed in children... more...

Related Diseases for Brain Stem Glioma

Diseases in the Brain Stem Glioma family:

Adult Brain Stem Glioma

Diseases related to Brain Stem Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Related Disease Score Top Affiliating Genes
1 diffuse intrinsic pontine glioma 30.9 ACVR1 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D
2 glioma 30.4 BRAF EGFR FGFR1 H3F3A HIST1H3A IDH1
3 medulloblastoma 29.7 EGFR FGFR1 IDH1 PDGFB PIK3CA TP53
4 childhood brain stem glioma 12.7
5 adult brain stem glioma 12.5
6 brain stem astrocytic neoplasm 11.2
7 brain stem ependymoma 11.2
8 brain ependymoma 10.3 EGFR TP53
9 nevus of ota 10.3 BRAF TP53
10 adult hepatocellular carcinoma 10.3 PIK3CA TP53
11 interval angle-closure glaucoma 10.3 IDH1 IDH2
12 irinotecan toxicity 10.3 EGFR UGT1A UGT1A1
13 rare adenocarcinoma of the breast 10.3 PIK3CA TP53
14 nervous system cancer 10.3 EGFR IDH1 TP53
15 cerebellar astrocytoma 10.3 IDH1 TP53
16 breast squamous cell carcinoma 10.3 EGFR PIK3CA TP53
17 malignant spiradenoma 10.3 PIK3CA TP53
18 enchondroma 10.3 IDH1 IDH2
19 gliomatosis cerebri 10.2 EGFR IDH1 TP53
20 penile cancer 10.2 EGFR PIK3CA TP53
21 brain glioma 10.2 EGFR IDH1 TP53
22 adenosquamous carcinoma 10.2 EGFR PIK3CA TP53
23 estrogen-receptor positive breast cancer 10.2 EGFR PIK3CA TP53
24 intracranial chondrosarcoma 10.2 IDH1 IDH2 TP53
25 pleomorphic xanthoastrocytoma 10.2 BRAF IDH1 TP53
26 breast carcinoma in situ 10.2 EGFR FGFR1 TP53
27 undifferentiated pleomorphic sarcoma 10.2 IDH1 IDH2 PIK3CA
28 adult oligodendroglioma 10.2 FGFR1 IDH1 IDH2
29 protoplasmic astrocytoma 10.2 IDH2 TP53
30 respiratory system cancer 10.2 EGFR PIK3CA TP53
31 pilocytic astrocytoma of cerebellum 10.2 BRAF IDH1 IDH2
32 bile duct adenocarcinoma 10.2 IDH1 IDH2 TP53
33 colorectal adenocarcinoma 10.2 BRAF EGFR TP53
34 anaplastic thyroid cancer 10.2 BRAF PIK3CA TP53
35 ovarian serous cystadenocarcinoma 10.2 BRAF PIK3CA TP53
36 uterine carcinosarcoma 10.2 EGFR PIK3CA TP53
37 hyperplastic polyposis syndrome 10.2 BRAF TP53
38 li-fraumeni syndrome 10.2 EGFR IDH1 TP53
39 intestinal disease 10.2 EGFR PIK3CA TP53
40 ganglioglioma 10.2 BRAF H3F3A TP53
41 anaplastic oligodendroglioma 10.2 EGFR IDH2
42 oral cavity cancer 10.2 EGFR PIK3CA TP53
43 asbestos-related lung carcinoma 10.2 EGFR PDGFB
44 pilomyxoid astrocytoma 10.2 BRAF FGFR1 HIST1H3B
45 renal cell carcinoma, papillary, 1 10.2 BRAF PIK3CA TP53
46 bone giant cell sarcoma 10.2 H3F3A H3F3B TP53
47 gastrointestinal system cancer 10.2 EGFR PIK3CA TP53
48 gliosarcoma 10.2 EGFR FGFR1 IDH1 TP53
49 intrahepatic cholangiocarcinoma 10.2 EGFR IDH1 IDH2 TP53
50 malignant giant cell tumor 10.2 H3F3A H3F3B TP53

Graphical network of the top 20 diseases related to Brain Stem Glioma:



Diseases related to Brain Stem Glioma

Symptoms & Phenotypes for Brain Stem Glioma

GenomeRNAi Phenotypes related to Brain Stem Glioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.65 ACVR1 PDGFB
2 Decreased substrate adherent cell growth GR00193-A-2 9.65 PDGFB
3 Decreased substrate adherent cell growth GR00193-A-3 9.65 ACVR1 BRAF PDGFB
4 Decreased substrate adherent cell growth GR00193-A-4 9.65 ACVR1 BRAF FGFR1 PDGFB
5 Increased cell migration GR00055-A-3 8.92 ACVR1 BRAF EGFR PIK3CA

MGI Mouse Phenotypes related to Brain Stem Glioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.56 ACVR1 BRAF EGFR FGFR1 H3F3B PDGFB
2 neoplasm MP:0002006 9.17 ACVR1 BRAF EGFR IDH2 PIK3CA TMPRSS11D

Drugs & Therapeutics for Brain Stem Glioma

Drugs for Brain Stem Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 286)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
2
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
3
Methotrexate Approved Phase 3,Phase 2,Phase 1 59-05-2, 1959-05-2 126941
4
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
5
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-75-2 4033
6
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
7
Levoleucovorin Approved, Investigational Phase 3,Phase 1 68538-85-2
8
Lomustine Approved, Investigational Phase 3,Phase 1 13010-47-4 3950
9
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
10
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
11
Dacarbazine Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 4342-03-4 5351166
12
Temozolomide Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 85622-93-1 5394
13
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
14
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 216974-75-3
15
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
16
Thioguanine Approved Phase 3 154-42-7 2723601
17
Procarbazine Approved, Investigational Phase 3,Phase 1 671-16-9 4915
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
21
Ondansetron Approved Phase 3 99614-02-5 4595
22
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
23
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
24
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
25
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
26
Dopamine Approved Phase 3,Early Phase 1,Not Applicable 51-61-6, 62-31-7 681
27
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
29 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
30
Isophosphamide mustard Phase 3,Phase 1,Phase 2 0
31 Hormone Antagonists Phase 3,Phase 2,Phase 1
32 Antirheumatic Agents Phase 3,Phase 2,Phase 1
33 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
34 Antimetabolites Phase 3,Phase 2,Phase 1
35 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
37 Hormones Phase 3,Phase 2,Phase 1
38 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
39 Calcium, Dietary Phase 3,Phase 2,Phase 1
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
43 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
44 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
45 Vitamin B9 Phase 3,Phase 2,Phase 1
46 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
47 Vitamin B Complex Phase 3,Phase 2,Phase 1
48 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
49 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
50 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 197)
# Name Status NCT ID Phase Drugs
1 Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Unknown status NCT01878266 Phase 3
2 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
3 Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Completed NCT01635140 Phase 3
4 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
5 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
8 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
9 Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma Not yet recruiting NCT02864888 Phase 3 Atengenal;Astugenal
10 Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma Not yet recruiting NCT02887040 Phase 3 Atengenal;Astugenal
11 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
12 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
13 Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma Unknown status NCT00024336 Phase 2 tamoxifen citrate
14 Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma Unknown status NCT00514397 Phase 2 motexafin gadolinium;temozolomide
15 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
16 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
17 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
18 Antineoplaston Therapy in Treating Patients With Brain Stem Glioma Completed NCT00003459 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
19 Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma Completed NCT00179881 Phase 2 Carboplatin;Thalomid
20 A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas Completed NCT01118377 Phase 2 Capecitabine
21 Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma Completed NCT00079339 Phase 1, Phase 2 tipifarnib
22 Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma Completed NCT01145170 Phase 2
23 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
24 ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors Completed NCT01756989 Phase 2 Thalidomide, etoposide, celecoxib
25 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
26 Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma Completed NCT00387790 Phase 2 motexafin gadolinium
27 Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas Completed NCT00042991 Phase 1, Phase 2 gefitinib
28 O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors Completed NCT00275002 Phase 2 O6-benzylguanine;temozolomide
29 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
30 Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma Completed NCT00028795 Phase 2 temozolomide
31 Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas Completed NCT01514201 Phase 1, Phase 2 Temozolomide;Veliparib
32 Irinotecan in Treating Patients With Recurrent Glioma Completed NCT00003134 Phase 2 irinotecan hydrochloride
33 Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma Completed NCT00003616 Phase 1, Phase 2 irinotecan hydrochloride
34 Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors Completed NCT00002619 Phase 2 carboplatin;thiotepa
35 Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor Completed NCT00004068 Phase 2 irinotecan hydrochloride;temozolomide
36 Carboplatin in Patients With Progressive Gliomas Completed NCT00002749 Phase 2 carboplatin
37 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
38 Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas Completed NCT01574092 Phase 2 Combination of two marketed drugs (irinotecan and cisplatin)
39 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
40 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
41 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
42 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
43 Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00003241 Phase 2 phenylacetate
44 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
45 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
46 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
47 Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
48 A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas Completed NCT00036569 Phase 2
49 Antineoplaston Therapy in Treating Patients With Brain Tumors Completed NCT00003457 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
50 Antineoplaston Therapy in Treating Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)

Search NIH Clinical Center for Brain Stem Glioma

Genetic Tests for Brain Stem Glioma

Anatomical Context for Brain Stem Glioma

MalaCards organs/tissues related to Brain Stem Glioma:

41
Brain, Spinal Cord, T Cells, Bone, Lung, Liver, Cerebellum

Publications for Brain Stem Glioma

Articles related to Brain Stem Glioma:

(show top 50) (show all 58)
# Title Authors Year
1
IDH1 Mutation in Brain Stem Glioma: Case Report and Review of Literature. ( 29682047 )
2018
2
Spontaneous complete regression of a brain stem glioma pathologically diagnosed as a high-grade glioma. ( 28808781 )
2017
3
Brain stem glioma with spinal cord involvement in a young with neurofibromatosis type 1. ( 24614250 )
2014
4
Comment to the paper "The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brain stem glioma" by Burzynski et al. ( 25142686 )
2014
5
Intracranial syphilitic gumma mimicking a brain stem glioma. ( 22723064 )
2012
6
Treatment of progressive brain stem glioma with bevacizumab: radiological, metabolic and histopathological aspects. ( 22048887 )
2012
7
Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. ( 21233173 )
2011
8
Shall we treat hydrocephalus associated to brain stem glioma in children? ( 21928037 )
2011
9
Diffuse brain stem glioma. ( 20212241 )
2010
10
DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma. ( 20363335 )
2010
11
Commentary on diffuse brain stem glioma in children. ( 19016114 )
2008
12
Brain stem glioma, a rare cause of hearing loss and dysequilibrium. ( 21063295 )
2008
13
Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. ( 17278121 )
2008
14
HSV encephalitis in a child with brain stem glioma: a rare complication of therapy. Case report and review of the neurosurgical literature. ( 17593375 )
2007
15
Somatostatin-receptor positive brain stem glioma visualized by octreoscan. ( 17627256 )
2007
16
Brain stem glioma: two case studies. ( 15695354 )
2005
17
Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report. ( 16187025 )
2005
18
Biopsy of brain stem glioma using motor-evoked potential mapping by direct peduncular stimulation and individual adjuvant therapy. Case report. ( 15699622 )
2005
19
ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. ( 14506149 )
2003
20
Brain stem glioma in a child: false diagnosis of radiation necrosis with FDG PET. ( 12555260 )
2003
21
Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. ( 12718563 )
2003
22
Recurrent haemorrhage from a malignant brain stem glioma: a review of the mechanisms of tumoural haemorrhage. ( 12948477 )
2003
23
Childhood Brain Stem Glioma Treatment (PDQAr): Patient Version ( 27227262 )
2002
24
Childhood Brain Stem Glioma Treatment (PDQAr): Health Professional Version ( 27010061 )
2002
25
Childhood Brain Stem Glioma Treatment (PDQAr): Health Professional Version ( 26389253 )
2002
26
Childhood Brain Stem Glioma Treatment (PDQAr): Health Professional Version ( 27227258 )
2002
27
Moyamoya disease associated with a brain stem glioma. ( 10855525 )
2000
28
Clinical management of brain stem glioma. ( 10332008 )
1999
29
Diffuse brain stem glioma. A review of stereotactic biopsies. ( 10392494 )
1999
30
Brain stem glioma--a study of 111 patients. ( 10921213 )
1999
31
Neuroimaging of pediatric brain stem diseases other than brain stem glioma. ( 9075252 )
1996
32
Bilateral jawline nodules in a child with a brain-stem glioma. Poststeroid panniculitis. ( 7492138 )
1995
33
Leptomyxid amebic meningoencephalitis mimicking brain stem glioma. ( 7611076 )
1995
34
Intra-arterial chemotherapy for brain stem glioma: report of four cases. ( 8108006 )
1994
35
Quality of survival among children treated for brain stem glioma. ( 8043460 )
1994
36
Brain-stem glioma growth patterns. ( 8433142 )
1993
37
Radiotherapy for pediatric brain stem glioma: radiation dose, response, and survival. ( 1407449 )
1992
38
Pathological laughter and brain stem glioma. ( 1640246 )
1992
39
Prolonged response to carboplatin in an infant with brain stem glioma. ( 1985722 )
1991
40
Brain stem glioma: the role of a biopsy. ( 1892569 )
1991
41
Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma. ( 1902547 )
1991
42
A case of dyschondroplasia associated with brain stem glioma: diagnosis by stereotactic biopsy. ( 2234348 )
1990
43
Nursing care of the child with a brain stem glioma. ( 2254841 )
1990
44
Chronic dysphagia, vomiting and gastroesophageal reflux as manifestations of a brain stem glioma: a case report. ( 2488955 )
1989
45
Hyperfractionated radiation therapy for brain-stem glioma: a phase I-II trial. ( 2709109 )
1989
46
Transient late magnetic resonance imaging changes suggesting progression of brain stem glioma: implications for entry criteria for phase II trials. ( 3054620 )
1988
47
Brain stem glioma mimicking progressive basilar artery thrombosis. ( 2834522 )
1988
48
Brain stem glioma presenting as gastro-oesophageal reflux. ( 3632023 )
1987
49
Orthostatic hypotension with lower brain stem glioma. ( 7161610 )
1982
50
Brain stem glioma in childhood: acute hemiplegic onset. ( 6269714 )
1981

Variations for Brain Stem Glioma

ClinVar genetic disease variations for Brain Stem Glioma:

6 (show top 50) (show all 162)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
3 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
4 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
5 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
6 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
9 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
10 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
11 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
12 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
13 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
14 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
15 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
16 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
17 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
18 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
19 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
20 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
21 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
22 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
23 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
24 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
25 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
26 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
27 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
28 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605
29 ACVR1 NM_001105.4(ACVR1): c.983G> A (p.Gly328Glu) single nucleotide variant Pathogenic rs387906589 GRCh37 Chromosome 2, 158622516: 158622516
30 ACVR1 NM_001105.4(ACVR1): c.983G> A (p.Gly328Glu) single nucleotide variant Pathogenic rs387906589 GRCh38 Chromosome 2, 157766004: 157766004
31 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
32 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh38 Chromosome 3, 179234296: 179234296
33 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
34 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 GRCh38 Chromosome 17, 7675124: 7675124
35 TP53 NM_000546.5(TP53): c.711G> A (p.Met237Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs587782664 GRCh37 Chromosome 17, 7577570: 7577570
36 TP53 NM_000546.5(TP53): c.711G> A (p.Met237Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs587782664 GRCh38 Chromosome 17, 7674252: 7674252
37 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
38 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
39 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
40 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
41 TP53 NM_000546.5(TP53): c.709A> G (p.Met237Val) single nucleotide variant Uncertain significance rs730882004 GRCh38 Chromosome 17, 7674254: 7674254
42 TP53 NM_000546.5(TP53): c.709A> G (p.Met237Val) single nucleotide variant Uncertain significance rs730882004 GRCh37 Chromosome 17, 7577572: 7577572
43 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
44 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
45 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
46 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
47 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh37 Chromosome 17, 7578443: 7578443
48 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh38 Chromosome 17, 7675125: 7675125
49 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
50 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh38 Chromosome 17, 7675995: 7675995

Expression for Brain Stem Glioma

Search GEO for disease gene expression data for Brain Stem Glioma.

Pathways for Brain Stem Glioma

Pathways related to Brain Stem Glioma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.19 BRAF EGFR FGFR1 H3F3A H3F3B HIST1H3A
2
Show member pathways
14.04 BRAF EGFR FGFR1 HIST1H3A HIST1H3B HIST1H3D
3
Show member pathways
13.85 BRAF EGFR FGFR1 H3F3A H3F3B HIST1H3A
4
Show member pathways
13.84 ACVR1 BRAF EGFR FGFR1 H3F3A H3F3B
5
Show member pathways
13.53 BRAF EGFR FGFR1 H3F3A H3F3B HIST1H3A
6
Show member pathways
13.47 BRAF EGFR FGFR1 H3F3A H3F3B HIST1H3A
7
Show member pathways
13.45 BRAF EGFR FGFR1 H3F3A H3F3B HIST1H3A
8
Show member pathways
13.44 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
9
Show member pathways
13.35 BRAF EGFR FGFR1 HIST1H3A HIST1H3B HIST1H3D
10
Show member pathways
13.27 BSG H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D
11
Show member pathways
13.13 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
12
Show member pathways
13.04 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
13
Show member pathways
13.01 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
14
Show member pathways
12.88 BRAF EGFR FGFR1 PDGFB PIK3CA TP53
15
Show member pathways
12.88 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
16 12.84 BRAF EGFR FGFR1 PDGFB PIK3CA TP53
17 12.76 BRAF EGFR FGFR1 PDGFB TP53
18
Show member pathways
12.76 BRAF EGFR FGFR1 PIK3CA TP53
19
Show member pathways
12.76 BRAF EGFR FGFR1 PDGFB PIK3CA TP53
20
Show member pathways
12.73 BRAF EGFR FGFR1 PDGFB PIK3CA
21
Show member pathways
12.72 EGFR FGFR1 PDGFB PIK3CA TP53
22
Show member pathways
12.71 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
23 12.64 BRAF EGFR FGFR1 PDGFB PIK3CA
24
Show member pathways
12.53 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
25
Show member pathways
12.52 BRAF EGFR FGFR1 PIK3CA TP53
26
Show member pathways
12.49 BRAF EGFR PDGFB PIK3CA TP53
27
Show member pathways
12.44 ACVR1 EGFR FGFR1 PIK3CA TP53
28
Show member pathways
12.39 BRAF EGFR FGFR1 PDGFB PIK3CA
29 12.3 BRAF EGFR FGFR1 PIK3CA TP53
30
Show member pathways
12.29 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
31
Show member pathways
12.21 BRAF EGFR FGFR1 PIK3CA TP53
32
Show member pathways
12.18 ACVR1 BRAF PIK3CA TP53
33 12.14 EGFR FGFR1 PIK3CA TP53
34 12.13 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
35 12.11 ACVR1 PDGFB PIK3CA TP53
36 12.08 BRAF EGFR PIK3CA TP53
37
Show member pathways
12.05 BRAF EGFR PIK3CA TP53
38
Show member pathways
12.02 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
39 11.98 BRAF EGFR PDGFB TP53
40 11.95 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
41 11.89 BRAF EGFR PIK3CA
42
Show member pathways
11.8 BRAF FGFR1 PIK3CA
43 11.74 BRAF EGFR TP53
44 11.72 EGFR FGFR1 IDH1 PIK3CA TP53
45
Show member pathways
11.71 EGFR H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D
46 11.49 BRAF EGFR FGFR1 PDGFB
47 11.39 BRAF EGFR FGFR1 PIK3CA
48 11.22 BRAF EGFR PIK3CA
49 11.21 HIST1H3A HIST1H3B HIST1H3D HIST1H3G HIST1H3H
50
Show member pathways
10.82 IDH1 IDH2

GO Terms for Brain Stem Glioma

Cellular components related to Brain Stem Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromosome GO:0005694 9.91 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
2 protein-containing complex GO:0032991 9.91 EGFR H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D
3 nucleosome GO:0000786 9.7 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
4 nuclear chromosome GO:0000228 9.5 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
5 Barr body GO:0001740 9.43 H3F3A H3F3B
6 nuclear nucleosome GO:0000788 9.17 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
7 membrane GO:0016020 10.33 ACVR1 BRAF BSG EGFR FGFR1 HIST1H3A
8 extracellular exosome GO:0070062 10.14 BSG H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D
9 extracellular region GO:0005576 10.1 EGFR FGFR1 H3F3A H3F3B HIST1H3A HIST1H3B

Biological processes related to Brain Stem Glioma according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 chromatin organization GO:0006325 9.99 HIST1H3A HIST1H3B HIST1H3D HIST1H3G HIST1H3H
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 BRAF EGFR FGFR1 PDGFB
3 nucleosome assembly GO:0006334 9.95 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
4 MAPK cascade GO:0000165 9.94 BRAF EGFR FGFR1 PDGFB
5 peptidyl-tyrosine phosphorylation GO:0018108 9.92 BRAF EGFR FGFR1 PDGFB
6 positive regulation of protein kinase B signaling GO:0051897 9.91 EGFR FGFR1 PDGFB PIK3CA
7 protein heterotetramerization GO:0051290 9.91 HIST1H3A HIST1H3B HIST1H3D HIST1H3G HIST1H3H
8 regulation of megakaryocyte differentiation GO:0045652 9.87 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
9 phosphatidylinositol phosphorylation GO:0046854 9.86 EGFR FGFR1 PDGFB PIK3CA
10 DNA replication-dependent nucleosome assembly GO:0006335 9.85 HIST1H3A HIST1H3B HIST1H3D HIST1H3G HIST1H3H
11 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 BRAF EGFR PIK3CA
12 liver development GO:0001889 9.83 EGFR PIK3CA UGT1A1
13 positive regulation of cell growth GO:0030307 9.83 EGFR H3F3A H3F3B
14 interleukin-7-mediated signaling pathway GO:0038111 9.83 HIST1H3A HIST1H3B HIST1H3D HIST1H3G HIST1H3H
15 cellular response to drug GO:0035690 9.8 BRAF EGFR TP53
16 positive regulation of MAP kinase activity GO:0043406 9.8 EGFR FGFR1 PDGFB
17 regulation of gene silencing by miRNA GO:0060964 9.8 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
18 regulation of gene silencing GO:0060968 9.77 HIST1H3A HIST1H3B HIST1H3D HIST1H3G HIST1H3H
19 embryo implantation GO:0007566 9.76 BSG H3F3A H3F3B
20 negative regulation of gene expression, epigenetic GO:0045814 9.7 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
21 salivary gland morphogenesis GO:0007435 9.65 EGFR FGFR1
22 NADP metabolic process GO:0006739 9.64 IDH1 IDH2
23 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.63 EGFR TP53
24 isocitrate metabolic process GO:0006102 9.6 IDH1 IDH2
25 pericentric heterochromatin assembly GO:0031508 9.58 H3F3A H3F3B
26 regulation of centromere complex assembly GO:0090230 9.57 H3F3A H3F3B
27 glyoxylate cycle GO:0006097 9.55 IDH1 IDH2
28 negative regulation of chromosome condensation GO:1902340 9.54 H3F3A H3F3B
29 telomeric heterochromatin assembly GO:0031509 9.52 H3F3A H3F3B
30 chromatin silencing at rDNA GO:0000183 9.5 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
31 telomere organization GO:0032200 9.17 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
32 protein phosphorylation GO:0006468 10.08 ACVR1 BRAF EGFR FGFR1 PDGFB PIK3CA
33 cellular protein metabolic process GO:0044267 10.04 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
34 blood coagulation GO:0007596 10.02 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G

Molecular functions related to Brain Stem Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.88 ACVR1 FGFR1 IDH1 IDH2 PDGFB UGT1A1
2 cadherin binding GO:0045296 9.76 BSG EGFR HIST1H3A HIST1H3B HIST1H3D HIST1H3G
3 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 9.61 H3F3A H3F3B TP53
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.56 EGFR FGFR1 PDGFB PIK3CA
5 nucleosomal DNA binding GO:0031492 9.5 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3D HIST1H3G
6 protein heterodimerization activity GO:0046982 9.4 BRAF EGFR H3F3A H3F3B HIST1H3A HIST1H3B
7 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.37 IDH1 IDH2
8 isocitrate dehydrogenase activity GO:0004448 9.32 IDH1 IDH2

Sources for Brain Stem Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....